ICLE 2022

Streamlining cell therapy manufacturing with CliniMACS Prodigy 2:08
Streamlining cell therapy manufacturing with CliniMACS Prodigy
Saskia Rösch • 6 Apr 2022
Implementing automation technology in the CGT space 1:28
Implementing automation technology in the CGT space
Saskia Rösch • 6 Apr 2022
Utilizing flow cytometry in CAR T-cell research 3:10
Utilizing flow cytometry in CAR T-cell research
Saskia Rösch • 6 Apr 2022
PiggyBac Transposon-generated CAR T-cells in solid tumors 1:13
PiggyBac Transposon-generated CAR T-cells in solid tumors
Shigeki Yagyu • 8 Apr 2022
CAR T-cell therapy for neuroblastoma 2:24
CAR T-cell therapy for neuroblastoma
Shigeki Yagyu • 8 Apr 2022
Optimizing the upscaling and outscaling of CAR T-cell therapies 4:06
Optimizing the upscaling and outscaling of CAR T-cell therapies
Saskia Rösch • 6 Apr 2022
Direct detection and isolation of CAR cells from patient samples 1:27
Direct detection and isolation of CAR cells from patient samples
Saskia Rösch • 6 Apr 2022
Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
Moving CAR T-cell therapies to earlier lines of therapy in multiple myeloma 2:30
Moving CAR T-cell therapies to earlier lines of therapy in multiple myeloma
Angela Krackhard • 6 Apr 2022
Engineering NK cell-based cancer treatments 1:22
Engineering NK cell-based cancer treatments
Juliane Mietz • 1 Apr 2022
Photoporation with polydopamine nanosensitizers for mRNA delivery to T cells 2:59
Photoporation with polydopamine nanosensitizers for mRNA delivery to T cells
Dominika Berdecka • 1 Apr 2022
Enhancing the long-term functionality of CAR-T cells in solid tumors 1:23
Enhancing the long-term functionality of CAR-T cells in solid tumors
Shigeki Yagyu • 8 Apr 2022
The benefits of PiggyBac transposon-mediated CAR-T cell technology 2:37
The benefits of PiggyBac transposon-mediated CAR-T cell technology
Shigeki Yagyu • 8 Apr 2022
Developing individualized cancer therapies with neoantigen-specific TCRs 4:27
Developing individualized cancer therapies with neoantigen-specific TCRs
Angela Krackhard • 6 Apr 2022
Improving immune-imaging tools to assess cancer immunotherapies 5:33
Improving immune-imaging tools to assess cancer immunotherapies
Angela Krackhard • 6 Apr 2022
An overview of mouse models to study cell therapies for cancer 3:25
An overview of mouse models to study cell therapies for cancer
Juliane Mietz • 1 Apr 2022
The content of VJRegenMed is intended for healthcare professionals